Outlook for patients with cSSTI worldwide
ZINFORO® offers an efficacious and potent treatment for your patients with cSSTI.1-5
Inadequacy of first-line treatment
Around 40% of patients with cSSTI caused by mixed pathogens received inappropriate initial antimicrobial agents.9,11
Failure of therapy
Inappropriate initial therapy may result in poor therapy outcome. Initial therapy failure is associated with higher mortality, prolonged hospitalisation and consequent increased cost burden.11
Day 3 non-response rates
In a retrospective cohort analysis of adult patients, it was observed that non-response rates at Day 3 among patients with cSSTI receiving empiric therapy with broad-spectrum antibiotics† were high.9
Longer duration of hospitalisation and antibiotic treatment and higher costs
In a retrospective cohort analysis of adult patients, it was observed that non-response to initial antibiotic therapy was associated with an overall10:
*Initial antibiotic treatment modification
This is defined as the need for a change in the initial antibiotic treatment due to insufficient response, adverse reaction, interaction with other drugs, non-suitability of the initial antibiotic based on the results of microbiological tests, or changes to the antibiotic therapy or addition of further agents, alone or in combination. The presence of comorbidities is associated with higher rates of initial treatment modification in patients with cSSTI.6
†Broad-spectrum antibiotics included vancomycin, cefazolin, piperacillin-tazobactam and ampicillin-sulbactam.10
The study does not include data specific to ZINFORO®. The study had the inherent limitations associated with a retrospective chart review because data were initially collected for clinical rather than research purposes. Hence, certain information may have been absent, incomplete or missed by data abstractors.
cSSTI, complicated skin and soft tissue infection; CAP, community-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus aureus.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.